GlobeNewsWire · RVMD · November 19, 2026
Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026

Get the app for more
Explore stock news, insights and company research.
Get the app → Source: GlobeNewsWire ↗